Figure 1.

PMA treatment leads to TP63 degradation in vitro but is not deterministic

(A) Schematic illustration of MTZ injury time course.

(B) An integrated violin and boxplot representing the Nuclear P63 integrated density/nuclear area quantification results of each time point (n = 2).

(C) Bar plot showing proportional composition of HBC state at each time point.

(D) Schematic illustration of the PMA-mediated HBC activation assay (top). Representative sum projected z stack confocal 63x images of vehicle-treated and 12h-long 50 nm-treated HBCs (below).

(E) An integrated violin and boxplot representing the Nuclear P63 integrated density/nuclear area quantification results of each time point (n = 3).

(F) An integrated violin and boxplot representing the Granularity I output from CellProfiler.

(G) Bar plot showing proportional composition of HBC state at each time point post-PMA treatment.

(H) Schematic illustration of the PMA-mediated HBC recovery assay (top). Representative sum projected z stack confocal 63x images of vehicle-treated and 12h-long 50 nm-treated HBCs (bottom).

(I) An integrated violin and boxplot representing the Nuclear P63 integrated density/nuclear area quantification results of each time point (n = 3).

(J) Bar plot showing proportional composition of HBC state at each time point post-PMA treatment and recovery. For (B, E, and I), dashed lines represent TP63 fluorescence expression level thresholds corresponding to HBC state. Right y axis color blocks on (B, E, and I) correspond to these states, shown in (C, G, and J). Extreme outliers were removed utilizing the Tukey method (1.5 x IQR) (E and I). For (E, F, and I) statistical significance was determined by one-way ANOVA followed by Dunnett’s test. For (E, F, and I): ^∗p < 0.05,^∗∗p < 0.001,^∗∗∗p < 0.0001 (E and I). For (F), mean and standard deviation is reported. Scale bars: 20 μm (D and H). See Table S2 for information about sample sizes and number of cells per condition.